The Poly-Med Mission

Setting the framework for our distinctive strategy in vertical integration and unique product offerings, the first patent applications are filed. US Patents 5,898,040 and 5,969,020 “Microporous polymeric foams and microtextured surfaces” were granted from these initial applications. These original patents disclose novel materials and processes to generate substrates for the…
Read More

Poly-Med Inc.'s corporate offices and R&D operations merge under one roof. This expanded facility allows growth into new operations; including dedicated extrusion and coating facilities along with enhanced analytical capabilities.

Our 100th patent application is submitted to the USPTO. US Patent 7,632,765 is granted from this application, disclosing inorganic-organic melted extruded fibers and constructs for use in advanced medical devices.

The first sustained release pharmaceutical, utilizing a proprietary Poly-Med polymer system, is officially launched in Germany. The polymeric base provides a stable, hydro-setting gel system to release the antibiotic doxycycline for 14 days.

In continuing support of Clemson University’s increased graduate student research and education, Poly-Med Inc. proudly employs three adjunct faculty professors.

In order to meet the increasing need for specialty engineering and manufacturing support, we are expanding. Our new state-of-the art facility will include additional offices and manufacturing areas for engineering, quality assurance, polymerization, textile conversion, and packaging.

Poly-Med opens a new 30,000sf state-of-the-art facility dedicated to expanding manufacturing and development demands. This new facility allows for more than double the manufacturing capabilities at Poly-Med.